2nd Peking University Urology Academic Forum | Professor Jianye Wang: Current Priorities, Clinical Challenges, and Future Directions in Urinary Continence and Pelvic Floor Disorders

2nd Peking University Urology Academic Forum | Professor Jianye Wang: Current Priorities, Clinical Challenges, and Future Directions in Urinary Continence and Pelvic Floor Disorders

Urinary continence and pelvic floor disorders represent an important subspecialty within urology. Conditions such as post-prostatectomy urinary incontinence and overactive bladder (OAB), which are particularly common in elderly populations, can severely compromise patients’ quality of life.
Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave 

Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave 

 Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer vaccines, and T-cell engagers—are actively being explored.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.

test

  document.getElementById("video").style.height=document.getElementById("video").scr
“50 Years of Hematopoietic Stem Cell Transplantation”

“50 Years of Hematopoietic Stem Cell Transplantation”

We were honored to hear from Professor Xiaojun Huang of Peking University People’s Hospital and the Peking University Institute of Hematology, who shared a comprehensive reflection on the global evolution of hematopoietic stem cell transplantation (HSCT). From Dr. Edward Donnall Thomas' foundational work to the creation of the Beijing Protocol, Professor Huang spotlighted how China’s innovations—including non–T-cell-depleted haploidentical transplantation—are transforming clinical practice worldwide.